Veracyte’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Veracyte focuses on developing molecular cytology that enables physicians to make treatment decisions at an early stage in patient care. Read more

Bonnie Anderson's photo - Chairman & CEO of Veracyte

Chairman & CEO

Bonnie Anderson

CEO Approval Rating

95/100

Founded:

2008

Status:

PublicNASDAQVCYT

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Asuragen is Veracyte's biggest rival. Asuragen was founded in 2006, and is headquartered in Austin, Texas. Asuragen competes in the Health Care Services industry. Asuragen generates $78.9M less revenue vs. Veracyte.

Pathway Genomics is one of Veracyte's top competitors. Pathway Genomics's headquarters is in San Diego, California, and was founded in 2008. Pathway Genomics operates in the Health Care Services industry. Pathway Genomics generates 2.37% of Veracyte's revenue.

AltheaDx is seen as one of Veracyte's top competitors. AltheaDx is a Private company that was founded in 1998 in San Diego, California. Like Veracyte, AltheaDx also works within the Biotechnology sector. Compared to Veracyte, AltheaDx has 122 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Proteocyte Diagnostics a competitor of Veracyte?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$84.4M

Veracyte's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 1.2B. Over the last four quarters, Veracyte's revenue has decreased by 33.2%. Specifically, in Q2 2020's revenue was $20.7M; in Q1 2020, it was $31.1M; in Q4 2019, it was $29.7M; in Q3 2019, Veracyte's revenue was $31M.

Acquisitions

No recent acquisitions found related to Veracyte

Veracyte Funding History

$28M$121M$133.8M$178.8M

Since Veracyte was founded in 2008, it has participated in 5 rounds of funding. In total Veracyte has raised $178.8M. Veracyte's last funding round was on Mar 2016 for a total of $45.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Mar 2016
$45M
Equity
Sep 2014
$12.8M

Domain Associates

IPO
Oct 2013
$65M

Series C
Jun 2013
$28M
Series B
Jun 2010
$28M

Total Funding: $178.8M

Since Veracyte was founded in 2008, it has participated in 5 rounds of funding. In total Veracyte has raised $178.8M. Veracyte's last funding round was on Mar 2016 for a total of $45.0M

Investments

No recent investments found related to Veracyte

Veracyte News

September 4, 2020MarketScreener

to Present at Upcoming Investor Conferences

(marketscreener.com) Veracyte, Inc. , a global genomic diagnostics company, announced today that Bonn... See more »
August 26, 2020Global Legal Chronicle

Veracyte, Inc.'s $194 Million Shares Offering

Fenwick & West LLP advised Veracyte, Inc. on the deal. Veracyte, Inc. (Nasdaq: VCYT), a pioneering ge... See more »
August 20, 2020Clinical Lab Products

Veracyte, MaviDx Partner on Ultra-High-Volume Covid-19 Test

The ultra-high-volume covid-19 test approach may enable processing of over 40,000 patient samples per... See more »
August 12, 2020MarketScreener

Corporate Presentation August 2020

(marketscreener.com) ANSWERS Corporate Presentation August 2020 Forward-Looking Statements This prese... See more »
August 8, 2020Global Legal Chronicle

Veracyte's $180 Million Common Stock Offering

Latham & Watkins LLP represented the underwriters in the offering. Veracyte, Inc. announced the prici... See more »
August 7, 2020BioSpace

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - Aug 07, 2020

Veracyte, Inc. announced the closing of its public offering of 6,900,000 shares of common stock, incl... See more »
August 5, 2020MarketScreener

Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases

(marketscreener.com) ePosters presented during ATS 2020 Virtual conference https://www.marketscreener... See more »

Veracyte Press Releases

June 9, 2020StreetInsider

Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay

SOUTH SAN FRANCISCO, Calif.--(BUSINESS...... See more »
May 7, 2020Business Wire

Veracyte to Present at the UBS Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at the UBS Virtual Global Healthcar... See more »
May 7, 2019StreetInsider

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares ... See more »
January 9, 2019StreetInsider

Veracyte to Present at the 21st Annual Needham Growth Conference

Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive o... See more »
October 21, 2017StreetInsider

Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA

Veracyte, Inc. (NASDAQ: VCYT) announced that data presented today at the 87th Annual Meeting of the A... See more »
September 13, 2017Business Wire

Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonn... See more »
July 30, 2017Accesswire

Veracyte Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 31, 2017 / Veracyte Inc. (NASDAQ: VCYT) will be discussing their ear... See more »

Veracyte Videos

Headquarters

6000 Shoreline Ct Suite 300

South San Francisco, California94080

1-650-243-6300

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Veracyte focuses on developing molecular cytology that enables physicians to make treatment decisions at an early stage in patient care. Veracyte was founded in 2008. Veracyte's headquarters is located in South San Francisco, California, USA 94080. It...

CEO

Veracyte's Chairman & CEO, Bonnie Anderson, currently has an approval rating of 95%. Veracyte's primary competitors are Asuragen, Pathway Genomics & AltheaDx.

Website

veracyte.com

Frequently Asked Questions about Veracyte

  1. When was Veracyte founded?

    Veracyte was founded in 2008
  2. Who is Veracyte's CEO?

    Veracyte's CEO is Bonnie Anderson
  3. How much revenue does Veracyte generate?

    Veracyte generates $84.4M in revenue
  4. How much funding does Veracyte have?

    Veracyte has historically raised $178.8M in funding
  1. Where is Veracyte's headquarters?

    Veracyte's headquarters is in South San Francisco California, USA
  2. How many employees does Veracyte have?

    Veracyte has 270 employees
  3. What sector does Veracyte operate in?

    Veracyte is in Pharmaceuticals, Biotechnology
  4. Who are Veracyte's competitors?

    Veracyte's top competitors are Asuragen, Pathway Genomics, AltheaDx